Q2 2025
Released Aug 5, 2025, before the open
10-Q filed Aug 5, 2025, 37 days after period end · 0000078003-25-000138
Q2 2025 · 10-Q
Revenue$14.65B$14.65B +10.3% vs Q2 2024+6.8% vs Q1 2025
Net Income$2.91B$2.91B +6,997.6% vs Q2 2024−1.9% vs Q1 2025
EPS Diluted$0.51$0.51 +5,000.0% vs Q2 2024−1.9% vs Q1 2025
Operating Cash Flowderived-$582,000,000N/M
Free Cash Flowderived-$1,200,000,000N/M
Margins · derived
Net margin19.9%+19.6 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $14.65B | $13.28B | $13.01B | $27.74B |
| Net Income | $2.91B | $41.00M | $2.33B | $9.91B |
| EPS Diluted | $0.51 | $0.01 | $0.41 | $1.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR